Exane Asset Management grew its holdings in DBV TECHNOLOGIE/S (NASDAQ:DBVT) by 115.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,000 shares of the company’s stock after purchasing an additional 75,000 shares during the period. Exane Asset Management owned approximately 0.24% of DBV TECHNOLOGIE/S worth $899,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of DBV TECHNOLOGIE/S by 1.4% in the third quarter. FMR LLC now owns 1,325,676 shares of the company’s stock valued at $29,775,000 after purchasing an additional 18,744 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of DBV TECHNOLOGIE/S by 4.7% in the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in shares of DBV TECHNOLOGIE/S by 42.8% in the third quarter. Perceptive Advisors LLC now owns 3,009,998 shares of the company’s stock valued at $67,604,000 after purchasing an additional 901,800 shares in the last quarter. First Midwest Bank Trust Division lifted its holdings in shares of DBV TECHNOLOGIE/S by 505.4% in the fourth quarter. First Midwest Bank Trust Division now owns 988,891 shares of the company’s stock valued at $6,349,000 after purchasing an additional 825,533 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of DBV TECHNOLOGIE/S in the third quarter valued at $8,512,000. Institutional investors own 44.96% of the company’s stock.

Shares of NASDAQ:DBVT opened at $6.91 on Monday. DBV TECHNOLOGIE/S has a 1 year low of $3.60 and a 1 year high of $26.89. The firm has a market cap of $410.71 million, a P/E ratio of -2.05 and a beta of 1.91.

A number of analysts have recently issued reports on the company. BidaskClub upgraded DBV TECHNOLOGIE/S from a “strong sell” rating to a “sell” rating in a report on Saturday, February 2nd. ValuEngine lowered DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Leerink Swann restated an “outperform” rating on shares of DBV TECHNOLOGIE/S in a report on Thursday, December 20th. Morgan Stanley reduced their target price on DBV TECHNOLOGIE/S from $26.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, December 20th. Finally, JMP Securities reduced their target price on DBV TECHNOLOGIE/S from $30.00 to $20.00 and set a “market outperform” rating for the company in a report on Thursday, December 20th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.93.

ILLEGAL ACTIVITY WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2019/02/11/dbv-technologie-s-dbvt-shares-bought-by-exane-asset-management.html.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: How is inflation measured?

Institutional Ownership by Quarter for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.